《新股消息》據報諾輝健康明起招股 引16基投認購1.24億美元
據《彭博》引述銷售文件指,內地癌症早期篩查產品製造商諾輝健康啟動招股工作,將於明日起公開招股,計劃發行約7,660萬股股份,招股價介乎每股22.7至26.66元,集資最多20.42億元。
銷售文件顯示,諾輝健康已建簿供機構投資者作初步認購,預期2月10日定價,並於2月18日掛牌。是次招股引入16家基石投資者,包括景順、清池資本、博裕、GIC等,合共認購1.24億美元等值股份。高盛及瑞銀為聯席保薦人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.